Loan & DebtJun 5, 2026, 08:46 AM
Vivos Therapeutics to Exchange Up to $4.5M Debt for Equity
AI Summary
Vivos Therapeutics, Inc. announced a binding agreement with its senior lender, Streeterville Capital, LLC, to exchange up to $4.5 million of outstanding debt into a combination of perpetual preferred stock and common stock. This agreement also includes a 90-day suspension of debt repayment calls and a 60-day suspension of Streeterville's sales of Company securities. The debt-to-equity exchange is contingent on the completion of new equity financings and aims to improve the Company's stockholders' equity, comply with Nasdaq listing standards, and enhance cash flow and liquidity by reducing debt service obligations.
Key Highlights
- Vivos Therapeutics entered a binding agreement with Streeterville Capital, LLC.
- To exchange up to $4.5 million of outstanding debt into preferred and common stock.
- Streeterville committed to suspend debt repayment calls for 90 days.
- Streeterville committed to suspend sales of Company securities for 60 days.
- The debt-to-equity exchange is contingent on completing new equity financings.
- Aims to improve stockholders' equity and comply with Nasdaq listing standards.
- Expected to lower debt service obligations and support cash flow and liquidity.
Price Impact
More from VVOS